Form 8-K Jazz Pharmaceuticals For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Jazz Pharmaceuticals (JAZZ) PT Raised to $208 at BMO Capital
May 8, 2019 7:48 AM EDTBMO Capital analyst Gary Nachman raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $208.00 (from $206.00) while maintaining a Outperform rating.
Nachman commented, "JAZZ delivered strong, high-quality 1Q results with impressive beats on both top and bottom lines while maintaining robust spending... More



